{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T01:50:19Z","timestamp":1769651419142,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"a Grant-in-Aid for the Encouragement of Scientists from the Japan Society for the Promotion of Science","award":["22H04387"],"award-info":[{"award-number":["22H04387"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipemia is characterized by a milky appearance of plasma, which can be easily detected using an automated clinical chemistry analyzer. To date, few studies have evaluated the relationship between lipemia values and clinical test data other than lipid parameters. This study aimed to analyze the relationship among lipemia, clinical test data, and associated disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study examined 730 specimens from patients with and without lipemia who visited the Niigata University Medical and Dental Hospital in Japan. The participants were divided according to their lipemia index (LIP) into non- (&lt;\u20091.5 LIP), low- (1.5\u20134.9 LIP), and high-lipemia (\u2265\u20095.0 LIP) groups. Twenty-seven clinical analytes were analyzed, and their associations with the extent of lipemia were investigated using group comparisons, multinomial logistic regression, and correlation analyses. The prevalence of dyslipidemia and liver disease was also evaluated in the lipemic group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The lipemic group exhibited higher total cholesterol and triglyceride levels than the non-lipemia group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). The high-lipemia group demonstrated significantly higher median liver chemistries than the non-lipemia group: aspartate aminotransferase, 27 U\/L (interquartile range [IQR], 22\u201335 U\/L) vs. 23 U\/L (IQR, 20\u201328 U\/L); gamma-glutamyltransferase, 39 U\/L (IQR, 26\u201379 U\/L) vs. 24 U\/L (IQR, 16\u201340 U\/L) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Individuals in the high-lipemia group had a higher complication rate of concomitant dyslipidemia and liver disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lipemia was associated with elevated lipid metabolism-related parameters and liver chemistries. The LIP can be used to evaluate risks associated with liver disease and dyslipidemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-025-02845-7","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T13:54:11Z","timestamp":1766843651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipemia and its associations with liver disease and dyslipidemia: a cross-sectional study"],"prefix":"10.1186","volume":"25","author":[{"given":"Mami","family":"Osawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunobu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ushiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"2845_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","volume":"52","author":"WT Garvey","year":"2003","unstructured":"Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453\u201362.","journal-title":"Diabetes"},{"key":"2845_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.11613\/BM.2014.008","volume":"24","author":"N Nikolac","year":"2014","unstructured":"Nikolac N. Lipemia: causes, interference mechanisms, detection and management. Biochem Med Zagreb. 2014;24:57\u201367.","journal-title":"Biochem Med Zagreb"},{"key":"2845_CR3","doi-asserted-by":"publisher","first-page":"E1258","DOI":"10.1152\/ajpendo.2000.279.6.E1258","volume":"279","author":"Y Park","year":"2000","unstructured":"Park Y, Grellner WJ, Harris WS, Miles JM. A new method for the study of chylomicron kinetics in vivo. Am J Physiol Endocrinol Metab. 2000;279:E1258\u201363.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2845_CR4","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1373\/clinchem.2004.038075","volume":"50","author":"MH Kroll","year":"2004","unstructured":"Kroll MH. Evaluating interference caused by lipemia. Clin Chem. 2004;50:1968\u20139.","journal-title":"Clin Chem"},{"key":"2845_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0022-2275(20)42827-5","volume":"31","author":"JC Cohen","year":"1990","unstructured":"Cohen JC, Berger GM. Effects of glucose ingestion on postprandial lipemia and triglyceride clearance in humans. J Lipid Res. 1990;31:597\u2013602.","journal-title":"J Lipid Res"},{"issue":"suppl. 1","key":"2845_CR6","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0021-9150(98)00226-3","volume":"141","author":"A van Tol","year":"1998","unstructured":"van Tol A, van der Gaag MS, Scheek LM, van Gent T, Hendriks HF. Changes in postprandial lipoproteins of low and high density caused by moderate alcohol consumption with dinner. Atherosclerosis. 1998;141(suppl. 1):S101-3.","journal-title":"Atherosclerosis"},{"key":"2845_CR7","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/jn\/129.6.1126","volume":"129","author":"LF Tinker","year":"1999","unstructured":"Tinker LF, Parks EJ, Behr SR, Schneeman BO, Davis PA. (n-3) fatty acid supplementation in moderately hypertriglyceridemic adults changes postprandial lipid and apolipoprotein B responses to a standardized test meal. J Nutr. 1999;129:1126\u201334.","journal-title":"J Nutr"},{"key":"2845_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/ajcn\/76.5.942","volume":"76","author":"KG Jackson","year":"2002","unstructured":"Jackson KG, Robertson MD, Fielding BA, Frayn KN, Williams CM. Olive oil increases the number of triacylglycerol-rich chylomicron particles compared with other oils: an effect retained when a second standard meal is fed. Am J Clin Nutr. 2002;76:942\u201349.","journal-title":"Am J Clin Nutr"},{"key":"2845_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.47102\/annals-acadmedsg.V35N11p790","volume":"35","author":"K-H Lim","year":"2006","unstructured":"Lim K-H, Lian W-B, Yeo C-L. Does visual turbidity correlate with serum triglyceride levels in babies on total parenteral nutrition? Ann Acad Med Singap. 2006;35:790\u20133.","journal-title":"Ann Acad Med Singap"},{"key":"2845_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plabm.2017.02.001","volume":"8","author":"S Mainali","year":"2017","unstructured":"Mainali S, Davis SR, Krasowski MD. Frequency and causes of lipemia interference of clinical chemistry laboratory tests. Pract Lab Med. 2017;8:1\u20139.","journal-title":"Pract Lab Med"},{"key":"2845_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.7861\/clinmedicine.13-3-309","volume":"13","author":"P Sen Gupta","year":"2013","unstructured":"Sen Gupta P, Sharma M, Timms PM. Laboratory samples deemed \u2018unsuitable for analysis\u2019 can be diagnostically useful. Clin Med (Lond). 2013;13:309\u201311.","journal-title":"Clin Med (Lond)"},{"key":"2845_CR12","unstructured":"Burnett JR, Hooper AJ, Hegele RA. Familial lipoprotein lipase deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A, eds. GeneReviews\u00ae [Internet]. University of Washington: Seattle, WA, 1993 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1308\/"},{"key":"2845_CR13","doi-asserted-by":"publisher","first-page":"e0262748","DOI":"10.1371\/journal.pone.0262748","volume":"17","author":"G Tian","year":"2022","unstructured":"Tian G, Wu Y, Jin X, Zeng Z, Gu X, Li T, et al. The incidence rate and influence factors of hemolysis, lipemia, icterus in fasting serum biochemistry specimens. PLoS One. 2022;17:e0262748.","journal-title":"PLoS One"},{"key":"2845_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1440-1754.2001.00619.x","volume":"37","author":"PC Ng","year":"2001","unstructured":"Ng PC, Lam CW, Fok TF, Lee CH, Lo DY, Chan LY, et al. Deceptive hyperbilirubinaemia in a newborn with familial lipoprotein lipase deficiency. J Paediatr Child Health. 2001;37:314\u20136.","journal-title":"J Paediatr Child Health"},{"key":"2845_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.","journal-title":"BMC Gastroenterol"},{"key":"2845_CR16","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835.","journal-title":"Hepatology"},{"key":"2845_CR17","doi-asserted-by":"crossref","unstructured":"Havel RJ, Gordon RS Jr. Idiopathic hyperlipemia: metabolic studies in an affected family. J Clin Invest. 1960;39:1777\u201390.","DOI":"10.1172\/JCI104202"},{"key":"2845_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/BF00400640","volume":"38","author":"P Knudsen","year":"1995","unstructured":"Knudsen P, Eriksson J, Lahdenper\u00e4 S, Kahri J, Groop L, Taskinen MR, et al. Changes of lipolytic enzymes cluster with insulin resistance syndrome. Diabetologia. 1995;38:344\u201350.","journal-title":"Diabetologia"},{"key":"2845_CR19","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/ki.1993.388","volume":"44","author":"Y Nishizawa","year":"1993","unstructured":"Nishizawa Y, Shoji T, Nishitani H, Yamakawa M, Konishi T, Kawasaki K, et al. Hypertriglyceridemia and lowered apolipoprotein c-II\/c-III ratio in uremia: effect of a fibric acid, clinofibrate. Kidney Int. 1993;44:1352\u20139.","journal-title":"Kidney Int"},{"key":"2845_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1515\/CCLM.2006.040","volume":"44","author":"H De Haene","year":"2006","unstructured":"De Haene H, Taes Y, Christophe A, Delanghe J. Comparison of triglyceride concentration with lipemic index in disorders of triglyceride and glycerol metabolism. Clin Chem Lab Med. 2006;44:220\u20132.","journal-title":"Clin Chem Lab Med"},{"key":"2845_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/157016111795495594","volume":"9","author":"TC Ooi","year":"2011","unstructured":"Ooi TC, Robinson L, Graham T, Kolovou GD, Mikhailidis DP, Lairon D. Proposing a \u2018lipemic index\u2019 as a nutritional and research tool. Curr Vasc Pharmacol. 2011;9:313\u20137.","journal-title":"Curr Vasc Pharmacol"},{"key":"2845_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/09674845.2015.11666796","volume":"72","author":"L Cobbold","year":"2015","unstructured":"Cobbold L, Crook MA. The lipaemic index: clinical observations. Br J Biomed Sci. 2015;72:52\u20135.","journal-title":"Br J Biomed Sci"},{"key":"2845_CR23","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2021.021002","volume":"31","author":"J Van Elslande","year":"2021","unstructured":"Van Elslande J, Hijjit S, De Vusser K, Langlois M, Meijers B, Mertens A, et al. Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample. Biochem Med. 2021;31:021002.","journal-title":"Biochem Med"},{"key":"2845_CR24","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1373\/jalm.2018.028456","volume":"3","author":"YP Agrawal","year":"2019","unstructured":"Agrawal YP, Hall K. The lipemia index: an underutilized tool to detect monoclonal proteins. J Appl Lab Med. 2019;3:1062\u20134.","journal-title":"J Appl Lab Med"},{"key":"2845_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3343\/alm.2014.34.4.307","volume":"34","author":"DH Shin","year":"2014","unstructured":"Shin DH, Kim J, Uh Y, Lee SI, Seo DM, Kim KS, et al. Development of an integrated reporting system for verifying hemolysis, icterus, and lipemia in clinical chemistry results. Ann Lab Med. 2014;34:307\u201312.","journal-title":"Ann Lab Med"},{"key":"2845_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.11613\/BM.2019.020705","volume":"29","author":"J Cadamuro","year":"2019","unstructured":"Cadamuro J, Lippi G, von Meyer A, Ibarz M, van Dongen-Lases E, Cornes M, et al. European survey on preanalytical sample handling\u2014Part 2: practices of European laboratories on monitoring and processing haemolytic, Icteric and lipemic samples. Biochem Med (Zagreb). 2019;29:334\u201345.","journal-title":"Biochem Med (Zagreb)"},{"key":"2845_CR27","first-page":"5","volume":"4","author":"C Fern\u00e1ndez Prendes","year":"2023","unstructured":"Fern\u00e1ndez Prendes C, Castro Castro MJ, S\u00e1nchez Navarro L, Rap\u00fan Mas L, Morales Indiano C, Arrobas Velilla T. Handling of lipemic samples in the clinical laboratory. Adv Lab Med. 2023;4:5\u201327.","journal-title":"Adv Lab Med"},{"key":"2845_CR28","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1515\/cclm-2025-0319","volume":"63","author":"AH Kristoffersen","year":"2025","unstructured":"Kristoffersen AH, Hollestelle MJ, Cadamuro J, Hillarp A, Jennings I, Marrington R, et al. Practical handling of hemolytic, icteric and lipemic samples for coagulation testing in European laboratories. A collaborative survey from the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM). Clin Chem Lab Med. 2025;63:2074\u201384.","journal-title":"Clin Chem Lab Med"},{"key":"2845_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.5551\/jat.GL2022","volume":"31","author":"T Okamura","year":"2023","unstructured":"Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb. 2023;31:641\u2013853.","journal-title":"J Atheroscler Thromb"},{"key":"2845_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","volume":"112","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18\u201335.","journal-title":"Am J Gastroenterol"},{"key":"2845_CR31","unstructured":"Japanese Committee for Clinical Laboratory Standards (JCCLS). Japanese shared reference intervals: reference intervals for major clinical laboratory tests in Japan. 2022 ed. Tokyo: JCCLS; 2022 [in Japanese]."},{"key":"2845_CR32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.cca.2011.04.018","volume":"412","author":"K Nakajima","year":"2011","unstructured":"Nakajima K, Nakano T, Tokita Y, Nagamine T, Inazu A, Kobayashi J, et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta. 2011;412:1306\u201318.","journal-title":"Clin Chim Acta"},{"key":"2845_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1365-2362.1977.tb01651.x","volume":"7","author":"G Klose","year":"1977","unstructured":"Klose G, Windelband J, Weizel A, Greten H. Secondary hypertriglyceridaemia in patients with parenchymal liver disease. Eur J Clin Invest. 1977;7:557\u201362.","journal-title":"Eur J Clin Invest"},{"key":"2845_CR34","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"2845_CR35","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143\u2013421.","journal-title":"Circulation"},{"key":"2845_CR36","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1016\/j.jhep.2023.08.025","volume":"80","author":"H Perazzo","year":"2024","unstructured":"Perazzo H, Pacheco AG, Griep RH, Collaborators. Changing from NAFLD through MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort. J Hepatol. 2024;80:e72-4.","journal-title":"J Hepatol"},{"key":"2845_CR37","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80:e54\u20136.","journal-title":"J Hepatol"},{"key":"2845_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/jdi.12290","volume":"6","author":"T Nishi","year":"2015","unstructured":"Nishi T, Babazono A, Maeda T, Imatoh T, Une H. Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes. J Diabetes Investig. 2015;6:309\u201316.","journal-title":"J Diabetes Investig"},{"key":"2845_CR39","doi-asserted-by":"publisher","first-page":"e0180951","DOI":"10.1371\/journal.pone.0180951","volume":"12","author":"JH Huh","year":"2017","unstructured":"Huh JH, Kim JY, Choi E, Kim JS, Chang Y, Sung K-C. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One. 2017;12:e0180951.","journal-title":"PLoS One"},{"key":"2845_CR40","doi-asserted-by":"publisher","first-page":"1171754","DOI":"10.3389\/fcvm.2023.1171754","volume":"10","author":"Y Niu","year":"2023","unstructured":"Niu Y, Wang G, Feng X, Niu H, Shi W. Significance of fatty liver index to detect prevalent ischemic heart disease: evidence from National health and nutrition examination survey 1999\u20132016. Front Cardiovasc Med. 2023;10:1171754.","journal-title":"Front Cardiovasc Med"},{"key":"2845_CR41","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12072-012-9401-4","volume":"7","author":"MA Borman","year":"2013","unstructured":"Borman MA, Ladak F, Crotty P, Pollett A, Kirsch R, Pomier-Layrargues G, et al. The fatty liver index has limited utility for the detection and quantification of hepatic steatosis in obese patients. Hepatol Int. 2013;7:592\u20139.","journal-title":"Hepatol Int"},{"key":"2845_CR42","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/tmi.13927","volume":"28","author":"F Lajeunesse-Trempe","year":"2023","unstructured":"Lajeunesse-Trempe F, Boit MK, Kaduka LU, De Lucia-Rolfe E, Baass A, Paquette M, et al. Validation of the fatty liver index for identifying non-alcoholic fatty liver disease in a Kenyan population. Trop Med Int Health. 2023;28:830\u20138.","journal-title":"Trop Med Int Health"},{"key":"2845_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41:99\u2013109c.","journal-title":"Eur Heart J"},{"key":"2845_CR44","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1093\/jalm\/jfae057","volume":"9","author":"J Cao","year":"2024","unstructured":"Cao J, Donato L, El-Khoury JM, Goldberg A, Meeusen JW, Remaley AT. ADLM guidance document on the measurement and reporting of lipids and lipoproteins. J Appl Lab Med. 2024;9:1040\u201356.","journal-title":"J Appl Lab Med"},{"key":"2845_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2011.08.012","volume":"220","author":"KG Jackson","year":"2012","unstructured":"Jackson KG, Poppitt SD, Minihane AM. Postprandial lipemia and cardiovascular disease risk: interrelationships between dietary, physiological and genetic determinants. Atherosclerosis. 2012;220:22\u201333.","journal-title":"Atherosclerosis"},{"key":"2845_CR46","volume-title":"Hemolysis, icterus, and lipemia\/turbidity indices as indicators of interference in clinical laboratory analysis; approved guideline CLSI C56-A document","author":"Clinical Laboratory Standards Institute","year":"2012","unstructured":"Clinical Laboratory Standards Institute. Hemolysis, icterus, and lipemia\/turbidity indices as indicators of interference in clinical laboratory analysis; approved guideline CLSI C56-A document. Wayne, PA, USA: Clinical Laboratory Standards Institute; 2012."},{"key":"2845_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clinbiochem.2017.11.007","volume":"52","author":"L-J Cartier","year":"2018","unstructured":"Cartier L-J, Collins C, Lagac\u00e9 M, Douville P. Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. Clin Biochem. 2018;52:61\u20136.","journal-title":"Clin Biochem"},{"issue":"suppl 1","key":"2845_CR48","doi-asserted-by":"publisher","first-page":"SI20","DOI":"10.1016\/S0140-6736(97)90024-6","volume":"350","author":"M Syv\u00e4nne","year":"1997","unstructured":"Syv\u00e4nne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 1997;350(suppl 1):SI20\u20133.","journal-title":"Lancet"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02845-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:03:46Z","timestamp":1769609026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-025-02845-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2845"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02845-7","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Niigata University on 30 June 2022 (Approval number: 2022-0035). As this study used clinical analytes obtained during routine medical care and did not involve the collection or testing of new specimens, the requirement for informed consent was waived. The participants were provided with the option to opt out of the study if they declined to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}